Dr. Beltran on the Utility of Liquid Biopsies Versus Tissue Biopsies in CRPC-NE

Video

In Partnership With:

Himisha Beltran, MD, discusses the utility of liquid biopsies versus tissues biopsies in castration-resistant neuroendocrine prostate cancer.

Himisha Beltran, MD, associate professor of medicine, Lank Center for Genitourinary Oncology, Division of Molecular and Cellular Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the utility of liquid biopsies versus tissues biopsies in castration-resistant neuroendocrine prostate cancer (CRPC-NE).

An abstract presented at the 2020 Genitourinary Cancers Symposium demonstrated a high concordance between circulating tumor DNA (ctDNA) in plasma-based testing and tissue-based testing with regard to identifying common alterations in prostate cancer, says Beltran.

To look beyond common mutations, whole-exome sequencing across the genome was compared between sample types, says Beltran. Results showed that a higher genomic similarity between plasma and tissue samples was noted in the CRPC-NE subgroup compared with traditional CRPC, explains Beltran.

This suggests that there is less disease heterogeneity in men with CRPC-NE. Moreover, this complements other data that suggest as patients progress to more advanced disease, there is likely clonal selection of a resistant clone, concludes Beltran.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD